News

OmniTier joins Genomics England Discovery Forum to drive down cost of genome analysis

August 19th 2020

MILPITAS, Calif)--OmniTier Inc., an Edge computing acceleration company focused on providing high-throughput genome analysis solutions, announced it has joined join Genomics England’s Discovery Forum industry partnership as an Associate Member. 

The Discovery Forum provides a platform for collaboration and engagement between Genomics England, industry partners, academia, the NHS and the wider genomics landscape.  OmniTier will be working with the researchers, clinicians and analysts who have been successful in joining Genomics England’s Clinical Interpretation Partnership (GeCIP) within a managed framework. This partnership between industry, the academic research community and clinicians will help to accelerate the development of new diagnostics and treatments for NHS patients as all findings will have to be shared.

“Creation of knowledge databases that associate genomic variants to specific diseases is essential to the practice of precision medicine. One of the bottlenecks now is the length of time it takes to perform de novo assembly or reference genome alignment, along with detailed secondary analysis involving various types of variant calling”, said Dr Hemant Thapar, CEO of OmniTier. “OmniTier is focussed on continuing to drive down the cost and run-times of multi’omics analysis to help realize a future of affordable precision medicine.”

OmniTier’s CompStor Novos® scalable appliance supports both de novo assembly and reference alignment whilst offering best-in-class variant calling performance through a combination of GATK(1) and proprietary Novos based variant calling in whole genome sequencing (WGS) and whole exome sequencing (WES) applications. CompStor Novos enables breakthrough runtimes of between 2-6 hours per genome depending upon the number of servers in the cluster - enabling 10 times higher throughput on standard coverage genomes and lowering the per genome assembly costs by over 70% compared to alternative de novo pipelines.

The CompStor Novos® appliance is available today. For more information to schedule a product demonstration, visit www.omnitier.com or sales@omnitier.com.

 

About Genomics England

Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project (2). We are now moving towards a future of enabling faster, deeper genomic research, bringing genomic healthcare to all who need it.

 

About OmniTier Inc.

OmniTier provides advanced AI software and appliances benefiting from OmniTier’s high-performance, lower cost tiered memory technologies, that enable Edge Infrastructure and Edge Devices to deliver an affordable real-time, big data future.

It’s cost effective healthcare and genomic analysis appliances are focussed on providing high-throughput, class-leading accuracy and ease-of-use. Founded in 2015, the company has R&D operations in Milpitas, CA and Rochester, MN.

CompStor™ is a trademark of OmniTier, Inc.

(1) GATK (Genome Analysis Toolkit), developed by the Broad Institute (https://gatk.broadinstitute.org/hc/en-us)

(2) 100,000 Genomes Project (https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/

 

Contact:

Justin Cowling, VP Sales & Marketing

OmniTier Inc.
email: justin.cowling@omnitier.co

Recent Tweets:

OmniTier Inc.
@Omnitier

OmniTier Inc., an acceleration company enabling faster time-to-inference bioinformatics solutions, debuted the CompStorTM Novos platform for de novo assembly-based variant calling in whole genome sequencing (WGS) applications.

OmniTier Inc.
@Omnitier

OmniTier’s CompStor™ Brings De Novo Analytics to Genomics

Researchers in joint study cut time for de novo global assembly to under two hours with CompStor’s tiered-memory architecture; higher accuracy and a faster path to precision medicine

Join Our Mailing List